ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Alzheimer's 'grand slam' for Biogen and Eisai: five things to know

Treatment for dementia still faces financial and regulatory hurdles

An estimated 6 million people in Japan are suffering dementia, or 17% of the senior population. Eisai filed for approval to use aducanumab in Japan in December. (Source photos by Ken Kobayashi and Kosaku Mimura)

TOKYO -- U.S. regulators' approval on Monday of aducanumab, an Alzheimer's treatment jointly developed by Massachusetts-based Biogen and Tokyo-based Eisai, is potentially a life-changing moment for millions.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more